Epigenomes is a distinguished open access journal published by MDPI, dedicated to advancing the field of epigenetics and its interdisciplinary connections to biochemistry, genetics, and molecular biology. Since its inception in 2017, this journal has provided a transparent platform for researchers to share their findings, contributing to a deeper understanding of epigenetic mechanisms and their implications in health, toxicology, and mutagenesis. Ranked in the Q2 quartile across multiple categories, including biochemistry and genetics, Epigenomes is recognized for its scholarly contributions, reflected in its notable Scopus rankings. Readers benefit from a wealth of open access articles, fostering innovation and collaboration within the academic community. With its headquarters in Switzerland and an unwavering commitment to scientific rigor, Epigenomes is positioned as a vital resource for researchers, professionals, and students seeking to deepen their insights into the epigenomic landscape.

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.

Cardiovascular Toxicology is a pivotal journal dedicated to advancing the understanding of the interplay between toxic substances and cardiovascular health. Published by HUMANA PRESS INC, this journal serves as a critical resource for researchers and professionals in the fields of cardiology, toxicology, and molecular biology. With an ISSN of 1530-7905 and an E-ISSN of 1559-0259, it has established itself as a key source of high-quality research since its inception in 2001, continuing to contribute valuable insights through 2024. The journal enjoys a robust reputation, evidenced by its Q2 ranking in both Cardiology and Cardiovascular Medicine and Toxicology, along with a Q3 ranking in Molecular Biology for 2023. With Scopus rankings placing it in the 80th percentile for Cardiology and 71st for Toxicology, Cardiovascular Toxicology attracts submissions that reflect cutting-edge research and innovative methodologies. Notably, the journal prioritizes stringent peer review and scholarly rigor, ensuring that published works significantly impact the understanding of cardiovascular responses to various toxic agents. Though not an open-access journal, its content remains highly sought after in a diverse scholarly community, making it indispensable for those dedicated to enhancing cardiovascular disease prevention, diagnosis, and treatment through toxicological insights.

JOURNAL OF MEDICAL GENETICS, published by the BMJ PUBLISHING GROUP, stands as a premier platform in the field of genetics, focusing on both fundamental genetic research and its clinical applications. With a distinctive legacy dating back to 1965 and a significant role in advancing the understanding of genetic disorders, this journal has established itself in the top tiers with a commendable Q1 category ranking in both Genetics and Clinical Genetics as of 2023. The journal's impact is underscored by its Scopus rankings, placing it among the leading journals in the fields of medicine and genetics. Researchers and practitioners are drawn to its rigorous peer-review process and its commitment to disseminating high-quality research findings, critical reviews, and innovative clinical practices. While it is not an open-access journal, the insights provided are invaluable for anyone looking to deepen their knowledge or contribute to the burgeoning field of medical genetics.

European Journal of Medical Genetics, published by Elsevier, is a pivotal platform dedicated to advancing knowledge in the fields of medical genetics and its clinical applications. With an ISSN of 1769-7212 and an E-ISSN of 1878-0849, this journal fosters innovative research and insights into the genetic factors that influence human health. Ranked in the Q3 category for both Genetics and Clinical Genetics, and achieving notable recognition in Medicine (miscellaneous) with a Q2 positioning, it strives to bridge the gap between laboratory findings and clinical practice. Operating in an Open Access format, the journal aims at maximally disseminating essential findings to researchers, professionals, and students alike, ensuring that critical advances in genetics are accessible to the global medical community. With converged publication years spanning from 2005 to 2024, the journal strengthens its mission to be at the forefront of genetic research that informs clinical methodologies and fosters improved healthcare outcomes.

Application of Clinical Genetics is a premier open-access journal published by Dove Medical Press Ltd., dedicated to advancing the field of clinical genetics since its inception in 2008. Based in New Zealand, this journal has established itself as a significant resource for researchers, clinicians, and students alike, contributing to the body of knowledge in both genetic medicine and clinical applications. With an impact factor reflecting its contributions to the field, the journal holds positions in the Q2 and Q3 quartiles of the 2023 Genetics categories, showcasing its relevance and scientific merit. Furthermore, it ranks #43 out of 99 in Clinical Genetics and #153 out of 347 in Biochemistry, Genetics, and Molecular Biology, indicating robust performance amongst its peers. The journal’s broad scope, encompassing various aspects of clinical genetics, ensures that it remains at the forefront of critical discussions, innovative research, and applications essential for the progression of personalized medicine. Researchers and professionals are encouraged to explore its openly accessible content that fosters collaboration and the sharing of knowledge in this dynamic and rapidly evolving field.

GENETICS IN MEDICINE, published by Elsevier Science Inc, stands as a premier journal in the realms of clinical genetics and medicine. With an impressive impact factor and ranked #3 out of 99 in the category of Genetics (clinical), alongside a 97th percentile ranking in the Scopus database, this journal is recognized for its outstanding contribution to the field. Established in 1998, it aims to disseminate innovative research and clinical advancements bridging genetics and medical practice, making it essential reading for researchers, healthcare professionals, and students alike. Although not an open-access journal, GENETICS IN MEDICINE provides valuable insights into genetics that drive the future of personalized medicine and patient care. With a commitment to excellence, the journal continuously explores the evolving landscape of genetic research to foster the understanding and application of genetic principles in medical contexts.

Molecular Syndromology is a premier journal focused on the intricate connections between molecular genetics and syndromology, fostering discussions that advance our understanding of genetic disorders and their clinical implications. Published by KARGER, a distinguished name in medical and scientific publishing, this journal serves as a valuable platform for researchers, clinicians, and students in the field of genetics. With its ISSN 1661-8769 and E-ISSN 1661-8777, the journal has gained recognition in its category, currently positioned in the Q4 quartile for both genetic and clinical genetics disciplines according to the latest metrics. Despite being indexed lower in Scopus rankings, it addresses crucial gaps in research and offers open access options that enhance visibility and dissemination of knowledge. As it continues to converge from 2010 to 2024, Molecular Syndromology aims to bridge the gap between molecular research and its clinical applications, making a significant impact in the evolving landscape of genetic medicine.

Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

The EUROPEAN JOURNAL OF HUMAN GENETICS, published by SpringerNature, stands as a preeminent platform in the field of genetics and clinical genetics. Established in 1993, this prestigious journal, with an ISSN of 1018-4813 and an E-ISSN of 1476-5438, has consistently maintained its position in the Q1 quartile for both Genetics and Clinical Genetics categories as of 2023, reflecting its significant contributions to the field. Its impact is further underscored by its impressive Scopus rankings, placing it in the 92nd percentile among clinical genetics journals. The journal aims to disseminate cutting-edge research, case studies, and reviews that advance our understanding of human genetics, promoting collaboration and innovation among researchers, professionals, and students alike. While it does not currently offer open access, the journal provides substantial value through its rigorous peer review process and commitment to quality. As it continues to shape the future of genetic research through 2024 and beyond, the EUROPEAN JOURNAL OF HUMAN GENETICS remains an essential resource for those dedicated to exploring the complexities of human heredity.